Previous Section
Clinical Trials
1. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
- Author
- Quintas-Cardama A; Kantarjian H; Garcia-Manero G; O'Brien S; Faderl S; Estrov Z; Giles F; Murgo A; Ladie N; Verstovsek S; Cortes J;
- Institution
- Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
- Journal
- Cancer. 2007 Jan 15;109(2):248-55.
- Abstract URL
- Click here to view abstract
2. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
- Author
- Kantarjian H; Giles F; Wunderle L; Bhalla K; O'Brien S; Wassmann B; Tanaka C; Manley P; Rae P; Mietlowski W; Bochinski K; Hochhaus A; Griffin JD; Hoelzer D; Albitar M; Dugan M; Cortes J; Alland L; Ottmann OG;
- Institution
- Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX 77230-1402, USA. hkantarj@mdanderson.org
- Journal
- N Engl J Med. 2006 Jun 15;354(24):2542-51.
- Abstract URL
- Click here to view abstract
3. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
- Author
- Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL;
- Institution
- Department of Leukemia, M.D. Anderson Cancer Center, Houston, USA.
- Journal
- N Engl J Med. 2006 Jun 15;354(24):2531-41.
- Abstract URL
- Click here to view abstract
4. Imatinib therapy prior to myeloablative allogeneic stem cell transplantation.
- Author
- Zaucha JM; Prejzner W; Giebel S; Gooley TA; Szatkowski D; Kalwak K; Wojnar J; Kruzel T; Balon J; Holowiecki J; Hellmann A;
- Institution
- Department of Hematology, Medical University of Gdansk, Gdansk, Poland. jzaucha@amg.gda.pl
- Journal
- Bone Marrow Transplant. 2005 Sep;36(5):417-24.
- Abstract URL
- Click here to view abstract
5. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
- Author
- Bornhauser M; Kroger N; Schwerdtfeger R; Schafer-Eckart K; Sayer HG; Scheid C; Stelljes M; Kienast J; Mundhenk P; Fruehauf S; Kiehl MG; Wandt H; Theuser C; Ehninger G; Zander AR;
- Institution
- Medizinische Klinik und Poliklinik I, Universitatsklinikum Carl Gustav Carus, Dresden, Germany. martin.bornhaeuser@uniklinikum-dresden.de
- Journal
- Eur J Haematol. 2006 Jan;76(1):9-17.
- Abstract URL
- Click here to view abstract
6. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy.
- Author
- Borthakur G; Kantarjian H; Daley G; Talpaz M; O'Brien S; Garcia-Manero G; Giles F; Faderl S; Sugrue M; Cortes J;
- Institution
- Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
- Journal
- Cancer. 2006 Jan 15;106(2):346-52.
- Abstract URL
- Click here to view abstract
7. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation.
- Author
- Millot F; Guilhot J; Nelken B; Leblanc T; De Bont ES; Bekassy AN; Gadner H; Sufliarska S; Stary J; Gschaidmeier H; Guilhot F; Suttorp M;
- Institution
- Department of Hematology, CHU la Miletrie, Poitiers, France. f.millot@chu-poitiers.fr
- Journal
- Leukemia. 2006 Feb;20(2):187-92.
- Abstract URL
- Click here to view abstract
8. Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naive, chronic-phase chronic myelogenous leukemia.
- Author
- Lipton JH; Khoroshko N; Golenkov A; Abdulkadyrov K; Nair K; Raghunadharao D; Brummendorf T; Yoo K; Bergstrom B;
- Institution
- Department of Medical Oncology, Princess Margaret Hospital, Toronto, ON, Canada. jeff.lipton@uhn.on.ca
- Journal
- Leuk Lymphoma. 2007 Mar;48(3):497-505.
- Abstract URL
- Click here to view abstract
9. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
- Author
- Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P;
- Institution
- Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77230-1402, USA. hkantarj@mdanderson.org
- Journal
- Blood. 2007 Nov 15;110(10):3540-6. Epub 2007 Aug 22.
- Abstract URL
- Click here to view abstract
10. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia.
- Author
- Olavarria E; Siddique S; Griffiths MJ; Avery S; Byrne JL; Piper KP; Lennard AL; Pallan L; Arrazi JM; Perz JB; O'Shea D; Goldman JM; Apperley JF; Craddock CF;
- Institution
- Department of Haematology, Imperial College, Hammersmith Hospital, London, UK.
- Journal
- Blood. 2007 Dec 15;110(13):4614-7. Epub 2007 Sep 19.
- Abstract URL
- Click here to view abstract
Next: Immunotherapy
